A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
A phase 2 trial of EIK1001, Pembrolizumab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Eikon Therapeutics, active and no longer recruiting.
Overview
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC is a phase 2 interventional study registered as NCT06246110 by Eikon Therapeutics, with 70 participants enrolled, started 2024-02-06 and due to reach its primary completion in 2026-12. Interventions recorded: EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed and Carboplatin.
Similar pages
not linked directly; found by shared links- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Pemetrexed, Carboplatin, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.